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As at December 2014, there were 5016 Australians living after being diagnosed with MPN during the preceding 10 years. Of these, 1848 (36.8%) had been diagnosed with PV, 2448 (49%) with ET, and 720 (14.4%) with PMF. This 10-year prevalence likely under-estimates the true prevalence of MPN, as many MPN patients are likely to be alive more than 10 years after diagnosis.
However, since registration of MPN only started in Australian for diagnoses from 2003 onwards, we are unable to report longer term prevalence estimates.
The incidence of all classic MPNs combined was generally higher among males than females (incidence rate ratio = 1.27, P < 0.001) (Table 1 ) including patients with PV or PMF in each age group. However, for ET there were more females than males overall, and up to the 50 to 69 year age group.
The burden of these diseases is heaviest among the elderly. Incidence increased with age (Table 1 and Supporting Information Figure S1 ), with the median age at diagnosis for all cases of MPN being 68 years, ranging from 66 years for ET, 67 years for PV to 72 years for PMF. The excess mortality relative to age-matched controls was also higher among older than younger patients (Supporting Information Table S1 , Supporting Information Figure S3 ). For example, the excess hazard was nearly three times higher (EHR = 2.97 [2.3-3 .9]) for Australians diagnosed when aged 50 to 69 years compared to those diagnosed when aged 15 to 49 years old, and seven times higher for those aged 70 to 89 years at diagnosis (EHR = 7.30 [5.6-9.5]). The age effect was particularly pronounced for people diagnosed with ET. Given that vascular complications account for a large proportion of MPN-associated mortality, it is possible that prevalent vascular risk factors in older individuals interact to amplify the disease-specific risk. 4, 5 Determination of the specific causes of death was not possible within this study, but understanding the factors that contribute to excess mortality could help clinicians to address factors that may reduce this risk. Figure S2 ). There was no evidence of a change in the magnitude or direction of the trend over this period. to diagnosis are commonly observed. 6 Further investigations and capture-recapture studies are needed to clarify the factors that may have led to these changes in reported incidence.
Overall, the 5-year relative survival for MPN was 80.8% (Supporting Information Table S1 ), reducing to 67.7% by 10 years after diagnosis.
This varied by type of MPN, with 5-year survival for ET (86.1%) and PV (91.1%) being substantially higher than for PMF (50.1%). After adjusting for age group at diagnosis, survival for all classic MPNs was about 50%
worse among males (Excess Hazard Ratio = 1.51, 95% confidence inter- Information Table S1 , Supporting Information Figure S3 ). This significantly worse prognosis for males The crude probability of death from MPN was calculated using functions of the expected mortality rates, the excess mortality rate and the all-cause mortality rates. Of 100 Australians diagnosed with MPN, we would expect about 29 to have died from the disease within 10 years of diagnosis, 19 to have died from other causes and 52 to remain alive (Supporting Information Table S2 ). Of Australians diagnosed with ET, 16% would be expected to have died from their MPN within 10 years, compared with 24% diagnosed with PV, and 64% diagnosed with PMF. The mortality burden increases as age increases, both for the number of deaths due to MPN and number of deaths due to other causes (Supporting Information Figure S4 ).
Our study adds to a body of data from multiple countries with different mixes of race and ethnicity showing an apparent change in incidence patterns of MPN. These changes, particularly the declining rate of PV diagnosis, are still unexplained, but may reflect changes in investigation and reporting rather than a true change in incidence. As is the case for most population-based registries, cancer registries in Australia do not routinely collect information about genetic testing, and so this precludes the opportunity to investigate how diagnosis and prognosis varies according to somatic driver mutations in different age and sex cohorts. Accurate enumeration of the MPNs is reliant on cancer registries having appropriate notification processes for these cancers.
Accurate population-based reporting, including the collection of genetic information, is needed to facilitate future studies of MPN etiology and to assess whether changes in practice alter survival.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article. Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure
To the Editor:
Graft failure (GF) is a rare but severe event after allogeneic hematopoietic stem cell transplantation (HSCT), leading to increased mortality through infections, disease relapse and drawbacks of marrow aplasia. 1 Retrospective studies have estimated the overall incidence of GF around 5.5%. 1, 2 Hematological risk factors such as non-malignant underlying diseases, partial remission at transplant, HLA mismatch, use of a cord blood source and low graft cellularity are consistently associated with GF. [1] [2] [3] In most studies, infections are cited as circumstantial events but to date, no study has specifically documented early-onset severe infections (ESIs) associated with GF. The present study focuses on the incidence, the chronology, the type and the outcome of ESIs during the expected engraftment period in the setting of GF after allogeneic HSCT.
We conducted a retrospective, observational, multicentric matched case-control (1:2) study among adult allogeneic HSCT recipients trans- ESIs were defined as life-threatening fungal, viral, parasitic or bacterial infection occurring upon conditioning (day 7 before HSCT) until day 42 post-HSCT using the most recent consensus definitions from international groups provided in Supporting Information Table S1 .
Cumulative incidence and survivals were calculated using the Fine and Gray competing risk regression model. Competing events were death from all causes for the cumulative incidence of ESIs, and infection-free death for the cumulative survival rate of infectionrelated death. Analyses were based on two-sided P-values, with statistical significance defined by P < 0.05 and conducted with R software version 3.4.3.
Over the study period, 2094 allogeneic HSCT were performed.
Forty-nine GF were ultimately selected, including 45 (91.8%) primary GF and 4 (8.2%) early secondary GF. Full baseline characteristics are provided in Supporting Information Table S2 .
In univariate analysis, ESIs were strongly associated with GF 
